|Description||MJN110 is a potent and selective monoacylglycerol lipase (MAGL) inhibitor that modulates the synaptic processes. MJN110 has the potential for the treatment of acute nausea and vomiting as well as anticipatory nausea by elevation of endogenous cannabinoid 2-arachidonoylglycerol (2-AG) levels in the brain.|
|Brife Description||MAGL inhibitor|
|Synonyms||MJN-110; MJN 110; MJN110;2,5-dioxopyrrolidin-1-yl 4-(bis(4-chlorophenyl)methyl)piperazine-1-carboxylate|
KML-29, a effective MAGL inhibitor, has been found to have probable effect against neuropathic pain. IC50: 15, 43, and 5.9 nM (mouse, rat, and human brain prote...
JZP 361 is a reversible, potent and selective inhibitor of human recombinant MAGL (hMAGL) with IC50 value of 46 nM. It shows affinity for H1 receptors but shows...
SAR-629 is a Monoglyceride lipase (MGL) inhibitor and can also be known as 2-arachidonoylglycerol (2-AG) degradation inhibitor. MGL is a serine hydrolase which ...
NF 1819 is a selective irreversible β-lactam-based monoacylglycerol lipase inhibitor with IC50 values of 0.25 and 7.4 nM at rMAGL and hMAGL.
JJKK 048, a benzodioxol derivative, has been found to a MAGL inhibitor that could probably be significant in anticancer and anti-inflammatory studies. IC50: 0.4...
MJN110 is a potent and selective monoacylglycerol lipase (MAGL) inhibitor that modulates the synaptic processes. MJN110 has the potential for the treatment of a...
Endocannabinoids such as 2-arachidonoyl glycerol (2-AG) and arachidonoyl ethanolamide are biologically active lipids that are involved in a number of synaptic p...
JZL 184 is the first selective inhibitor of monoacylglycerol lipase (MAGL) with IC50 of 8 nM.